7 citations
,
October 2019 in “Annals of palliative medicine” This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.
4 citations
,
November 2022 in “British Journal of Cancer” This study found that men with a cutaneous melanoma diagnosis had an increased risk of subsequently being diagnosed with prostate cancer compared to those without melanoma.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.
January 2026 in “Clinical & Translational Oncology” This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.
November 2025 in “Cancer Cell International” This study provides a detailed cellular atlas of cutaneous squamous cell carcinoma, indicating that different fibroblast subtypes play roles in tumor progression and suppression, with potential biomarkers identified for HPV-related tumor growth.